Exceptionally Large
and Innovative Pipeline
The
prostate cancer pipeline is among the largest in the pharmaceutical industry
with 484 products in active development across all stages. The range of
mechanisms of action employed by these compounds is also highly diverse,
especially in comparison to the existing market landscape. More pertinently,
the degree and proportion of breakthrough innovations in this pipeline is
exceptional; Publisher analysis identified 174 first-in-class programs in the
prostate cancer pipeline, acting on 122 first-in-class molecular targets. This
accounts for some 36% of all products with a disclosed molecular target and is
reflective of the high degree of innovation in this indication. This has
far-reaching strategic implications for all market participants, as, despite
the high attrition rate in prostate cancer, it is highly likely many of the
first-in-class technologies will reach the market over the coming decade and
may transform the clinical and commercial landscape.
Alignment of
First-in-Class Molecular Target with Disease Causation
One
of the key trends in oncology and in prostate cancer in particular over the
last decade is the clinical and commercial impact of targeted therapies
designed to target proteins in signaling pathways that are strongly associated
with disease progression. By aligning the molecular targets for therapeutic
intervention with disease causation and/or propagation, these therapies limit
the systemic cytotoxic effects whilst inhibiting tumor-promoting signaling
pathways. Such strategies thereby typically achieve superior efficacy and
safety profiles.
Our
proprietary analyses demonstrate significant levels of differentiation as to
how well the first-in-class products and their respective molecular targets
align to underlying gene and protein level mutations and dysfunction. More
advanced analytics further substantiated these findings as strong levels of
differentiation in the scientific and clinical rationale for first-in-class
molecular targets emerged. Furthermore, clear frontrunners were identified by
integrating analyses to assess the accessibility of molecular targets for
therapeutic compounds, the size of the target patient population that would
benefit from therapeutic intervention, and the expected positioning of the
first-in-class products based on the molecular targets and mechanisms of action
of currently marketed products.
These
insights and a detailed review of the available evidence from scientific
studies substantiate the perspective that first-in-class-product technology in
its own right is not sufficient to offer a compelling scientific and clinical
rationale. However, a range of products offer very significant scientific and
clinical promise and could therefore result in a strong commercial proposition
with the prospect of clinically and commercially transformative products in the
future.
A Deals Landscape
with Numerous Investment Opportunities
Analysis
has confirmed that 169 of the 174 first-in-class products have not been
involved in a licensing or co-development deal. Although many act on targets
that are not yet strongly substantiated in terms of their therapeutic potential
in prostate cancer in clinical studies, there are many which are supported by
promising in vivo and in vitro preclinical evidence, and as such are highly
promising prostate cancer therapies. Indeed, breakthrough innovations are
highly desirable as an investment option.
However,
most deals involving first-in-class products were either preclinical or Phase I
development, whereas advance-in-class and addition-to-class product deals were
typically made in Phases II and III, therefore showing significant differentiation.
These findings have significant strategic implications for both biotech
companies seeking to out-license products and firms with an interest in
in-licensing first-in-class products with strong clinical and commercial
prospects.
Scope
The
report analyzes innovation in prostate cancer, in the context of the overall
pipeline and current market landscape. In addition, it analyzed the deals
landscape surrounding first-in-class products in prostate cancer, and pinpoints
opportunities for in-licensing. The report covers and includes -
- A brief introduction to prostate cancer, including symptoms, pathophysiology,
and overview of pharmacotherapy and treatment algorithms.
- The changing molecular target landscape between market and pipeline and
particular focal points of innovation in the pipeline.
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on
the basis of stage of development, molecule type and molecular target.
- Identification and assessment of first-in-class molecular targets with a
particular focus on early-stage programs of which clinical utility has yet to
be evaluated, as well as literature reviews on novel molecular targets.
- Assessment of the licensing and co-development deal landscape for prostate
cancer therapies and benchmarking of deals involving first-in-class versus
non-first-in-class-products.
Reasons to buy
The
report will assist business development and enable marketing executives to
strategize their product launches, by allowing them to -
- Understanding of the focal shifts in molecular targets in the prostate cancer
pipeline.
- Understanding of the distribution of pipeline programs by phase of development,
molecule type and molecular target.
- Access a scientific and clinical analysis of first-in-class developmental
programs for prostate cancer, benchmarked against non-first-in-class targets.
- Access a list of the first-in-class therapies potentially open to deal-making
opportunities
Spanning over 91 pages, “Frontier
Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class
Innovation” report covering the Executive
Summary, The Case for Innovation in Prostate Cancer, Clinical and Commercial
Landscape, Assessment of Pipeline Product Innovation, Signaling Network,
Disease Causation and Innovation Alignment, First-in-Class Target and Pipeline
Program Evaluation, Deals and Strategic Consolidations, Appendix.
